Breaking News Instant updates and real-time market news.

2022-07-01 12:17:02 $NSD NASDAQ Market Internals / + 12:17 07/01/22 07/01 12:17 07/01/22 12:17	NASDAQ market internals summary Volume is above average for this time of day. Breadth is mixed with issues bearish, volume is bullish and new highs to new lows are bearish. Advancing Issues: 1937 / Declining Issues: 2193 -- for a ratio of 0.9 to 1. Advancing Volume: 1,170,784,000 / Declining Volume: 1,077,133,000 -- for a ratio of 1.1 to 1. New 52-Week Highs: 9 / New 52-Week Lows: 263.

2022-07-01 12:17:02

$NSD

NASDAQ Market Internals

/ +

12:17

07/01/22

07/01

12:17

07/01/22

12:17

NASDAQ market internals summary

Volume is above average for this time of day. Breadth is mixed with issues bearish, volume is bullish and new highs to new lows are bearish. Advancing Issues: 1937 / Declining Issues: 2193 -- for a ratio of 0.9 to 1. Advancing Volume: 1,170,784,000 / Declining Volume: 1,077,133,000 -- for a ratio of 1.1 to 1. New 52-Week Highs: 9 / New 52-Week Lows: 263.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	ARC Group says RM2 continues to experience 'record demand' for BLOCKPal pallets » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 ARCW ARC Group $1.00 / + (+0.00%) ARC Group Worldwide… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Hot Stocks	Aptinyx announces NYX-2925 study did not achieve primary endpoint » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 APTX Aptinyx / + Aptinyx announced results… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options APTX Aptinyx / + 04/20/22 Aptinyx says NYX-783 data suggest potential as a treatment for PTSD 04/07/22 Aptinyx trading resumes 04/07/22 Aptinyx trading halted, news pending 04/07/22 Aptinyx announces NYX-2925 study did not achieve primary endpoint APTX Aptinyx / + 05/18/22 Piper Sandler Aptinyx price target lowered to $6 from $10 at Piper Sandler 04/14/22 H.C. Wainwright Aptinyx price target lowered to $2 from $8 at H.C. Wainwright 04/08/22 BMO Capital Aptinyx price target lowered to $6 from $12 at BMO Capital 04/08/22 Truist Aptinyx price target lowered to $5 from $12 at Truist APTX Aptinyx / + 08/04/22 Aptinyx reports Q2 EPS (26c), consensus (28c) 05/12/22 Aptinyx reports Q1 EPS (29c), consensus (30c) 03/23/22 Aptinyx reports Q4 EPS (29c), consensus (35c) APTX Aptinyx / + 03/23/22 Aptinyx options imply 6.9% move in share price post-earnings
Hot Stocks	Unity: UBX1325 injection led to clinically meaningful improvement in mean BCVA » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 UBX Unity Biotechnology / + UNITY Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 07:17 Today Unity Biotechnology announces anticipated milestones 07:17 Today Unity Biotechnology expects cash to fund operations through 1Q23 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Downgrade	Diebold downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 DBD Diebold $4.46 / -0.13 (-2.83%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Diebold rises 23.3% 05/10/22 Diebold expects to see cost savings of $150M in the next 12-18 months 03/17/22 Diebold: Shipments, sales into Russia suspended since start of Ukraine crisis DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Wedbush Wedbush upgrades Diebold, sees sales and earnings positioned to improve 07/08/22 Wedbush Diebold upgraded to Outperform from Neutral at Wedbush 05/10/22 JPMorgan Diebold downgraded to Neutral at JPMorgan after 'material' guidance cut 05/10/22 JPMorgan Diebold downgraded to Neutral from Overweight at JPMorgan DBD Diebold $4.46 / -0.13 (-2.83%) 08/02/22 Diebold lowers FY22 revenue view to $3.55B-$3.75B from $3.7B-$3.9B 08/02/22 Diebold reports Q2 non-GAAP EPS 38c, consensus (14c) 05/10/22 Diebold lowers FY22 revenue view to $3.7B-$3.9B from $4.0B-$4.2B 05/10/22 Diebold reports Q1 non-GAAP EPS ($1.61), consensus (21c) DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Plexus downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 PLXS Plexus $95.69 / +0.88 (+0.93%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PLXS Plexus $95.69 / +0.88 (+0.93%) 08/08/22 Plexus opens manufacturing facility in Bangkok, Thailand PLXS Plexus $95.69 / +0.88 (+0.93%) 07/29/22 Needham Plexus price target raised to $105 from $93 at Needham 07/27/22 Benchmark Plexus initiated with a Buy at Benchmark 06/07/22 Raymond James Plexus upgraded to Outperform from Market Perform at Raymond James 01/28/22 Needham Plexus price target lowered to $90 from $95 at Needham PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Plexus sees Q4 GAAP EPS $1.19-$1.35, consensus $1.10 07/27/22 Plexus reports Q3 adjusted EPS $1.33, consensus $1.10 04/27/22 Plexus reports Q2 EPS 95c, consensus 99c 03/07/22 Plexus reaffirms Q2 EPS guidance 76c-92c, consensus 99c PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/24/22 Plexus
Downgrade	Cognex downgraded to Underweight from Neutral at JPMorgan » 07:19 08/12/22 08/12 07:19 08/12/22 07:19 CGNX Cognex $48.48 / +0.54 (+1.13%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CGNX Cognex $48.48 / +0.54 (+1.13%) 06/09/22 Cognex discloses fire at primary manufacturing facility in Indonesia 03/03/22 Cognex authorizes up to $500M stock buyback program CGNX Cognex $48.48 / +0.54 (+1.13%) 08/03/22 Needham Cognex price target lowered to $50 from $60 at Needham 08/03/22 Cowen Cognex price target lowered to $55 from $75 at Cowen 08/03/22 Stephens Cognex downgraded to Equal Weight at Stephens on logistics demand deteriorating 08/03/22 Stephens Cognex downgraded to Equal Weight from Overweight at Stephens CGNX Cognex $48.48 / +0.54 (+1.13%) 08/02/22 Cognex sees Q3 revenue $160M-$180M, consensus $290.25M 08/02/22 Cognex reports Q2 adjusted EPS 41c, consensus 41c 05/05/22 Cognex sees Q2 revenue $265M-$285M, consensus $292.72M 05/05/22 Cognex reports Q1 EPS 42c, consensus 38c CGNX Cognex $48.48 / +0.54 (+1.13%) 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/02/22 Fly Intel: After-Hours Movers 02/17/22 Fly Intel: After-Hours Movers
Recommendations	Six Flags price target lowered to $28 from $35 at Stifel » 07:18 08/12/22 08/12 07:18 08/12/22 07:18 SIX Six Flags $21.12 / -4.685 (-18.16%) Stifel analyst Steven… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags falls -22.5% 08/11/22 Six Flags falls -21.5% 08/11/22 Six Flags falls -18.1% 08/11/22 Six Flags reports Q2 attendance 6.7M vs. 8.5M a year ago, down 22% SIX Six Flags $21.12 / -4.685 (-18.16%) 05:44 Today KeyBanc Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2 08/11/22 KeyBanc Six Flags downgraded to Sector Weight from Overweight at KeyBanc 07/08/22 Citi Six Flags downgraded to Neutral from Buy at Citi 06/24/22 Stifel Six Flags price target lowered to $35 from $52 at Stifel SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags reports Q2 EPS 53c, consensus $1.02 08/10/22 Notable companies reporting before tomorrow's open 08/10/22 Notable companies reporting before tomorrow's open 05/12/22 Six Flags reports Q1 EPS (76c), consensus ($1.04) SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/11/22 Fly Intel: Pre-market Movers 07/21/22 Fly Intel: After-Hours Movers
Hot Stocks	Unity Biotechnology announces anticipated milestones » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 UBX Unity Biotechnology / + UBX1325 24-week safety… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 07:17 Today Unity Biotechnology expects cash to fund operations through 1Q23 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	Toast price target raised to $25 from $18 at KeyBanc » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 TOST Toast $18.12 / -0.33 (-1.79%) KeyBanc analyst Josh Beck… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast up 9% to $19.80 after smaller than expected Q2 loss, raised guidance 07/26/22 Cathie Wood's ARK Investment bought 113K shares of Toast today 07/07/22 Toast acquires employee scheduling, communication solution Sling, no terms 05/13/22 Toast rises 15.2% TOST Toast $18.12 / -0.33 (-1.79%) 05/17/22 Mizuho Toast price target lowered to $18 from $19 at Mizuho 05/13/22 Needham Toast price target lowered to $21 from $38 at Needham 05/13/22 Canaccord Toast price target lowered to $25 from $34 at Canaccord 05/09/22 Mizuho Toast price target lowered to $19 from $23 at Mizuho TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B 08/11/22 Toast sees Q3 revenue $700M-$730M, consensus $665.08M 08/11/22 Toast reports Q2 EPS (11c) vs (64c) last year 08/11/22 Notable companies reporting after market close 22 Sep TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Fly Intel: After-Hours Movers 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 05/13/22 Fly Intel: Pre-market Movers TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast Inc options imply 11.3% move in share price post-earnings 05/12/22 Toast Inc options imply 21.6% move in share price post-earnings 03/04/22 Toast Inc put volume heavy and directionally bearish 02/15/22 Toast Inc options imply 15.0% move in share price post-earnings
Hot Stocks	PLx Pharma announces survey data on VAZALORE 81 mg » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 PLXP PLx Pharma $2.59 / +0.015 (+0.58%) PLx Pharma, with its lead… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 05/20/22 PLx Pharma showcases VAZALORE at SCAI annual meeting PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 03/15/22 BWS Financial BWS drops coverage of PLx Pharma, says off Amazon again 12/07/21 Raymond James Raymond James upgrades PLx Pharma on 'compelling entry point' 12/07/21 Raymond James PLx Pharma upgraded to Outperform from Market Perform at Raymond James 11/12/21 JMP Securities PLx Pharma reported strong quarter for Vazalore, says JMP Securities PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 06:55 Today PLx Pharma reports Q2 EPS (52c), consensus (56c) 05/13/22 PLx Pharma reports Q1 non-GAAP EPS (66c), consensus (72c) 03/11/22 PLx Pharma reports Q4 adjusted EPS (73c), consensus (71c) 08:30 Today PLx Pharma - PLXP

Hot Stocks	Unity Biotechnology expects cash to fund operations through 1Q23 » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 UBX Unity Biotechnology / + Cash, cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 04/28/22 Allogene Therapeutics appoints Lundeen as Chief People Officer UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	Illumina price target lowered to $300 from $480 at Stifel » 07:16 08/12/22 08/12 07:16 08/12/22 07:16 ILMN Illumina $227.64 / +0.44 (+0.19%) Stifel analyst Daniel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina cuts FY22 core Illumina revenue growth view to 3.5%-4.5% 08/11/22 Illumina drops 22% to $177 after Q2 results miss estimates, FY22 guidance cut 06/09/22 Illumina drops 6% to $210.00 after departure of CFO 06/09/22 Illumina CFO Sam Samad to depart, Joydeep Goswami named interim CFO ILMN Illumina $227.64 / +0.44 (+0.19%) 06:59 Today Citi Illumina price target lowered to $200 from $220 at Citi 06:36 Today Baird Illumina price target lowered to $215 from $306 at Baird 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler 07/14/22 Canaccord Illumina merger challenge not reflection of merits, says Canaccord ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina cuts FY22 adjusted EPS view to $2.75-$2.90 from $4.00-$4.20 08/11/22 Illumina reports Q2 adjusted EPS 57c, consensus 65c 08/11/22 Notable companies reporting after market close 05/05/22 Illumina sees FY22 adjusted EPS $4.00-$4.20, consensus $4.15 ILMN Illumina $227.64 / +0.44 (+0.19%) 07/27/22 Illumina's Grail deal likely to be blocked by EU regulators, Reuters reports 07/13/22 Illumina lost bid to block EU watchdog review of Grail deal, Bloomberg reports ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Fly Intel: After-Hours Movers 07/13/22 What You Missed On Wall Street On Wednesday 07/13/22 What You Missed On Wall Street This Morning 06/10/22 What You Missed On Wall Street On Friday 09/10/22 ESMO Congress 2022 ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina options imply 6.5% move in share price post-earnings 06/13/22 Illumina put buyer realizes 25% same-day gains 05/18/22 Early notable gainers among liquid option names on May 18th
Earnings	Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year » 07:16 08/12/22 08/12 07:16 08/12/22 07:16 UBX Unity Biotechnology / + Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 04/28/22 Allogene Therapeutics appoints Lundeen as Chief People Officer UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	CS Disco price target lowered to $30 from $40 at Stifel » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 LAW CS Disco $28.96 / +0.39 (+1.37%) Stifel analyst J. Parker… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly LAW CS Disco $28.96 / +0.39 (+1.37%) 06/06/22 DISCO appoints Tom Furr as CMO 06/01/22 CS Disco falls -10.8% 04/28/22 DISCO appoints Jignasha Amin Grooms as CHRO LAW CS Disco $28.96 / +0.39 (+1.37%) 06:15 Today BofA CS Disco downgraded to Neutral from Buy at BofA 06:05 Today Canaccord CS Disco downgraded to Hold from Buy at Canaccord 05:40 Today Cowen Cowen cuts CS Disco to Market Perform as momentum hits 'big snag' 05:35 Today Cowen CS Disco downgraded to Market Perform from Outperform at Cowen LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M 08/11/22 CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M 08/11/22 CS Disco reports Q2 adjusted (23c), consensus (27c) 05/12/22 CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M 15 Sep LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 Fly Intel: After-Hours Movers 05/12/22 Fly Intel: After-Hours Movers
Earnings	Real Good Food raises FY22 revenue $155M-$160M from $150M-$160M » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 RGF Real Good Food $6.93 / -0.11 (-1.56%) FY22 revenue consensus… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events RGF Real Good Food $6.93 / -0.11 (-1.56%) 08/09/22 Real Good Food Company Inc trading resumes 08/09/22 Real Good Food Company Inc trading halted, volatility trading pause 07/06/22 Real Good Food launches Real Good Foods Perks Program 06/07/22 Real Good Food announces launch of chicken enchiladas in Sam's Club RGF Real Good Food $6.93 / -0.11 (-1.56%) 03/08/22 Roth Capital Real Good Food initiated with a Buy at Roth Capital 11/30/21 Fly Intel: Top five analyst initiations 11/30/21 Jefferies Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months 11/30/21 Truist Real Good Food initiated with a Buy at Truist RGF Real Good Food $6.93 / -0.11 (-1.56%) 07:14 Today Real Good Food reports Q2 revenue $30.809M, consensus $32.12M 05/13/22 Real Good Food sees FY22 revenue $150M-$160M, consensus $143.65M 05/13/22 Real Good Food reports Q1 revenue $37.6M, consensus $32.47M 03/11/22 Real Good Food sees 2022 revenue $140M-$150M, consensus $120.57M 05 Nov 08:30 Today Real Good Food - RGF
General news	Market Update: » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 $ECON Economic Data / + Market Update: Stock… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly $ECON Economic Data / + 06/22/22 President Biden calls on Congress to suspend federal gas tax 05/19/22 Could crypto crash be good for U.S. economy? Probably. 05/12/22 Miller calls out Taylor Morrison, GM as names that may work in this environment 04/21/22 Powell says 50 basis point hike on table for May meeting $ECON Economic Data / + $ECON Economic Data / + 06/14/22 Ackman says 100 point hike tomorrow 'would be better' than 75 $ECON Economic Data / + 07/26/22 Ackman says biggest risk to economy is inflation, not higher rates 06/17/22 White House, Congress in talks over bill to fight inflation, Bloomberg says 06/13/22 Fed more likely to consider 0.75 point hike given recent data, WSJ says 05/10/22 Tepper says covered Nasdaq short, CNBC reports $ECON Economic Data / + 07/27/22 What You Missed On Wall Street On Wednesday 07/21/22 What You Missed On Wall Street On Thursday 07/21/22 What You Missed On Wall Street This Morning 07/06/22 What You Missed On Wall Street On Wednesday
Earnings	Venus Concept sees 2022 revenue $110M-$113M, consensus $126.82M » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 VERO Venus Concept / + The Company now expects… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VERO Venus Concept / + 04/25/22 Venus Concept announces first patient treatment in study of Aime 03/31/22 Venus Concept submits FDA 510(k) for Aime robotic technology VERO Venus Concept / + 06/24/22 BTIG Venus Concept price target lowered to $5.50 from $7.00 at BTIG 11/12/21 Stifel Venus Concept price target trimmed to $2 at Stifel after Q3 miss VERO Venus Concept / + 07:14 Today Venus Concept reports Q2 EPS (16c), consensus (7c) 03/28/22 Venus Concept sees 2022 revenue $126M-$130M, consensus $125.9M 03/28/22 Venus Concept reports Q4 EPS (8c), consensus (10c) 09/29/22 7th Annual Healthcare Conference 08:00 Today Venus Concept - VERO
Earnings	Venus Concept reports Q2 EPS (16c), consensus (7c) » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 VERO Venus Concept / + Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VERO Venus Concept / + 04/25/22 Venus Concept announces first patient treatment in study of Aime 03/31/22 Venus Concept submits FDA 510(k) for Aime robotic technology VERO Venus Concept / + 06/24/22 BTIG Venus Concept price target lowered to $5.50 from $7.00 at BTIG 11/12/21 Stifel Venus Concept price target trimmed to $2 at Stifel after Q3 miss VERO Venus Concept / + 03/28/22 Venus Concept sees 2022 revenue $126M-$130M, consensus $125.9M 03/28/22 Venus Concept reports Q4 EPS (8c), consensus (10c) 09/29/22 7th Annual Healthcare Conference 08:00 Today Venus Concept - VERO
Downgrade	Cellebrite downgraded to Market Perform at William Blair after guidance cut » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 CLBT Cellebrite $5.28 / -0.4 (-7.04%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CLBT Cellebrite $5.28 / -0.4 (-7.04%) 07/05/22 Cellebrite and Chainalysis launch partnership 06/30/22 Cellebrite announces availability of Cellebrite Physcial Analyzer Ultra Series 05/05/22 Cellebrite announces upcoming release of Cellebrite Premium 04/06/22 Cellebrite announces national police force of EMEA expanded partnership CLBT Cellebrite $5.28 / -0.4 (-7.04%) 06:06 Today William Blair Cellebrite downgraded to Market Perform from Outperform at William Blair 05/16/22 Cowen Cellebrite price target lowered to $13 from $17 at Cowen 05/13/22 Deutsche Bank Cellebrite price target lowered to $10 from $11 at Deutsche Bank 02/24/22 JPMorgan Cellebrite initiated with an Overweight at JPMorgan CLBT Cellebrite $5.28 / -0.4 (-7.04%) 08/11/22 Cellebrite reports Q2 adjusted EPS 0c, consensus 3c 08/11/22 Cellebrite lowers FY22 revenue to $270M-$285M from $285M-$300M 05/12/22 Cellebrite sees FY22 revenue $285M-$300M, consensus $292.06M 05/12/22 Cellebrite reports Q1 adjusted EPS 1c, consensus 2c CLBT Cellebrite $5.28 / -0.4 (-7.04%) 02/24/22 What You Missed On Wall Street On Thursday 02/24/22 What You Missed On Wall Street This Morning 02/24/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Earnings	Real Good Food reports Q2 revenue $30.809M, consensus $32.12M » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 RGF Real Good Food $6.93 / -0.11 (-1.56%) "I am pleased with… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events RGF Real Good Food $6.93 / -0.11 (-1.56%) 08/09/22 Real Good Food Company Inc trading resumes 08/09/22 Real Good Food Company Inc trading halted, volatility trading pause 07/06/22 Real Good Food launches Real Good Foods Perks Program 06/07/22 Real Good Food announces launch of chicken enchiladas in Sam's Club RGF Real Good Food $6.93 / -0.11 (-1.56%) 03/08/22 Roth Capital Real Good Food initiated with a Buy at Roth Capital 11/30/21 Fly Intel: Top five analyst initiations 11/30/21 Jefferies Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months 11/30/21 Truist Real Good Food initiated with a Buy at Truist RGF Real Good Food $6.93 / -0.11 (-1.56%) 05/13/22 Real Good Food sees FY22 revenue $150M-$160M, consensus $143.65M 05/13/22 Real Good Food reports Q1 revenue $37.6M, consensus $32.47M 03/11/22 Real Good Food sees 2022 revenue $140M-$150M, consensus $120.57M 03/11/22 Real Good Food sees Q1 revenue $33M-$35M, consensus $27.33M 05 Nov 08:30 Today Real Good Food - RGF

Syndicate	Vigil Neuroscience announces $75M private placement finanicng » 07:13 08/12/22 08/12 07:13 08/12/22 07:13 VIGL Vigil Neuroscience $7.29 / +0.13 (+1.82%) Vigil Neuroscience… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events VIGL Vigil Neuroscience $7.29 / +0.13 (+1.82%) 08/01/22 Vigil Neuroscience presents preclinical data on VGL101 07/28/22 Vigil Neuroscience appoints Suzanne Bruhn to board of directors 07/27/22 Vigil Neuroscience granted orphan status for leukoencephalopathy treatment 06/07/22 Vigil gets HREC approval to begin study of VGL101 in healthy volunteers VIGL Vigil Neuroscience $7.29 / +0.13 (+1.82%) 02/01/22 Morgan Stanley Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts 02/01/22 Stifel Stifel starts Vigil Neuroscience at Buy with $24 price target 02/01/22 Guggenheim Vigil Neuroscience initiated with a Buy at Guggenheim 02/01/22 Stifel Vigil Neuroscience initiated with a Buy at Stifel VIGL Vigil Neuroscience $7.29 / +0.13 (+1.82%) 08/08/22 Vigil Neuroscience reports Q2 EPS (60c) vs ($7.48) last year 05/12/22 Vigil Neuroscience reports Q1 EPS (58c) vs. ($5.46) last year 03/25/22 Vigil Neuroscience reports Q4 EPS ($8.28) vs. ($2.86) a year ago 07 Jan VIGL Vigil Neuroscience $7.29 / +0.13 (+1.82%) 03/26/22 Opening Day: AN2 Therapeutics rises in public debut after upsized IPO 08/15/22 2022 Biotech Summer Summit
Recommendations	Brilliant Earth price target raised to $10 from $8 at KeyBanc » 07:13 08/12/22 08/12 07:13 08/12/22 07:13 BRLT Brilliant Earth $6.44 / -0.17 (-2.57%) KeyBanc analyst Noah… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly BRLT Brilliant Earth $6.44 / -0.17 (-2.57%) 07/12/22 Brilliant Earth launches Reflections Collection 07/05/22 Brilliant Earth announces opening of showroom at Pinecrest in Cleveland 06/07/22 Brilliant Earth launches men's fine jewelry collection 06/02/22 Brilliant Earth opens 19th showroom, first location in Minnesota BRLT Brilliant Earth $6.44 / -0.17 (-2.57%) 07/22/22 Piper Sandler Brilliant Earth downgraded to Neutral from Overweight at Piper Sandler 07/21/22 KeyBanc KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view 07/20/22 KeyBanc Brilliant Earth initiated with an Overweight at KeyBanc 06/29/22 Raymond James Brilliant Earth initiated with an Outperform at Raymond James BRLT Brilliant Earth $6.44 / -0.17 (-2.57%) 08/11/22 Brilliant Earth backs FY22 revenue view $450M-$470M, consensus $467.19M 08/11/22 Brilliant Earth reports Q2 adjusted EPS 6c, consensus 4c 05/12/22 Brilliant Earth lowers FY22 revenue view $450M-$470M from $485M-$500M 05/12/22 Brilliant Earth sees Q2 revenue $103M-$109M, consensus $115.74M 23 Sep BRLT Brilliant Earth $6.44 / -0.17 (-2.57%) 07/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Earnings	Aslan Pharmaceuticals reports Q2 EPS (4c) vs (2c) last year » 07:12 08/12/22 08/12 07:12 08/12/22 07:12 ASLN Aslan Pharmaceuticals / + Cash, cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings ASLN Aslan Pharmaceuticals / + 06/07/22 Aslan in collaboration to probe IL-13Ra1 subunit role in AD 06/06/22 Aslan Pharmaceuticals to host third webinar in KOL series 05/20/22 Aslan Pharmaceuticals presents poster on eblasakimab at 2022 SID meeting 05/10/22 Aslan Pharmaceuticals reports acceptance of abstract on Eblasakimab ASLN Aslan Pharmaceuticals / + 05/23/22 Piper Sandler Aslan Pharmaceuticals price target lowered to $3 from $8 at Piper Sandler 09/27/21 Piper Sandler Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive ASLN Aslan Pharmaceuticals / + 04/27/22 Aslan Pharmaceuticals reports Q1 EPS (19c) vs. (13c) last year 03/25/22 Aslan Pharmaceuticals reports Q4 EPS (15c), consensus (14c)
Earnings	Gencor Industries reports Q3 EPS (7c) vs. 16c last year » 07:12 08/12/22 08/12 07:12 08/12/22 07:12 GENC Gencor Industries $9.57 / -0.08 (-0.83%) Reports Q3 revenue $29.6M… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings GENC Gencor Industries $9.57 / -0.08 (-0.83%) 07/19/22 Gencor Industries transfers common stock listing to NYSE American GENC Gencor Industries $9.57 / -0.08 (-0.83%) 05/13/22 Gencor Industries reports Q2 EPS 3c vs 16c last year
Recommendations	Chicken Soup for the Soul price target raised to $52 from $40 at DA Davidson » 07:10 08/12/22 08/12 07:10 08/12/22 07:10 CSSE Chicken Soup for the Soul / + , RDBX Redbox $1.71 / + (+0.00%) , ROKU Roku $80.65 / -0.33 (-0.41%) DA Davidson analyst Tom… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CSSE RDBX ROKU CSSE Chicken Soup for the Soul / + 08/11/22 Chicken Soup for the Soul reports Q2 adjusted EBITDA $5.6M vs. $3.2M y/y 08/10/22 Nasdaq says Redbox trading to be halted following after-hours session on Aug. 10 08/09/22 Redbox's stockholders approve merger proposal with Chicken Soup for the Soul 07/14/22 Crackle, Popcornflix FAST channels launch on FuboTV RDBX Redbox $1.71 / + (+0.00%) 08/10/22 Nasdaq says Redbox trading to be halted following after-hours session on Aug. 10 08/09/22 Redbox's stockholders approve merger proposal with Chicken Soup for the Soul 06/14/22 Redbox down 22.5% in pre-market trading, remains most active on Stocktwits 06/13/22 Redbox up another 19% amid increase in StockTwits message volume ROKU Roku $80.65 / -0.33 (-0.41%) 08/03/22 Paramount+ to launch as a Premium Subscription within Roku Channel 07/28/22 Roku drops 25% to $63.40 after Q2 results, Q3 guidance miss estimates 07/26/22 Cathie Wood's ARK Investment bought 585K shares of Roku today 06/23/22 Crackle launches updated app on Roku devices CSSE RDBX ROKU CSSE Chicken Soup for the Soul / + 07/12/22 B. Riley Chicken Soup sees positive free cash flow by year-end, says B. Riley 06/14/22 DA Davidson DA Davidson likes Chicken Soup for the Soul amid strong box office, Redbox deal 05/27/22 B. Riley Redbox downgraded to Sell from Neutral at B. Riley 05/17/22 Guggenheim Chicken Soup for the Soul resumed with a Buy at Guggenheim RDBX Redbox $1.71 / + (+0.00%) 07/12/22 B. Riley Chicken Soup sees positive free cash flow by year-end, says B. Riley 06/14/22 DA Davidson DA Davidson likes Chicken Soup for the Soul amid strong box office, Redbox deal 05/27/22 B. Riley Redbox downgraded to Sell from Neutral at B. Riley 05/17/22 Guggenheim Chicken Soup for the Soul resumed with a Buy at Guggenheim ROKU Roku $80.65 / -0.33 (-0.41%) 08/10/22 MoffettNathanson MoffettNathanson downgrades Roku to sell on 'challenged' position 08/10/22 MoffettNathanson Roku downgraded to Underperform from Market Perform at MoffettNathanson 08/08/22 Pivotal Research Roku downgraded to Sell from Hold at Pivotal Research 08/03/22 Citi Roku price target lowered to $125 from $165 at Citi CSSE ROKU CSSE Chicken Soup for the Soul / + 08/11/22 Chicken Soup for the Soul reports Q2 EPS ($1.39), consensus (72c) 05/11/22 Chicken Soup for the Soul reports Q1 adjusted EPS (83c), consensus (71c) 03/31/22 Chicken Soup for the Soul reports Q4 EPS ($1.38), consensus (51c) ROKU Roku $80.65 / -0.33 (-0.41%) 07/28/22 Roku sees Q3 revenue roughly $700M, consensus $901.73M 07/28/22 Roku reports Q2 EPS (82c), consensus (68c) 07/28/22 Notable companies reporting after market close 04/28/22 Roku backs FY22 revenue growth view of 35% y/y, consensus $3.72B ROKU ROKU Roku $80.65 / -0.33 (-0.41%) 06/14/22 Netflix talked with Roku, Comcast about ad sales, The Information reports 06/08/22 Roku staff 'buzzing' about possibility of being bought by Netflix, Insider says 05/06/22 Microsoft working on Xbox Cloud streaming device for TVs, VentureBeat says 05/03/22 Roku, Apollo team to bid for minority stake in Starz, WSJ reports CSSE RDBX ROKU CSSE Chicken Soup for the Soul / + 08/11/22 Fly Intel: After-Hours Movers 05/11/22 What You Missed On Wall Street On Wednesday 05/11/22 What You Missed On Wall Street This Morning RDBX Redbox $1.71 / + (+0.00%) 08/07/22 Short Report: Bed Bath Beyond in short-squeeze spotlight 08/01/22 Short Report: Bets against Beyond Meat pared as McPlant test ends 07/16/22 Short Report: Canoo shorts going along for the ride 07/09/22 Short Report: Carvana, Bed Bath Beyond short interest continues to grow ROKU Roku $80.65 / -0.33 (-0.41%) 08/10/22 What You Missed On Wall Street On Wednesday 08/10/22 What You Missed On Wall Street This Morning 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/08/22 What You Missed On Wall Street On Monday 09/08/22 Consumer/Media/Entertainment Conference 09/12/22 Chicken Soup for the Soul - CSSE 09/08/22 Roku CSSE RDBX ROKU CSSE Chicken Soup for the Soul / + 08/11/22 Chicken Soup for the Soul Entertainment options imply 14.7% move in share price post-earnings 08/03/22 Largest borrow rate increases among liquid names 07/15/22 Largest borrow rate increases among liquid names 07/01/22 Largest borrow rate increases among liquid names RDBX Redbox $1.71 / + (+0.00%) 06/15/22 Unusually active option classes on open June 15th 06/10/22 Redbox Entertainment Inc call volume above normal and directionally bullish 06/08/22 Unusually active option classes on open June 8th 06/07/22 Redbox Entertainment Inc call volume above normal and directionally bullish ROKU Roku $80.65 / -0.33 (-0.41%) 08/02/22 Roku call volume above normal and directionally bullish 08/01/22 Unusually active option classes on open August 1st 07/28/22 Roku options imply 10.5% move in share price post-earnings 06/08/22 Unusually active option classes on open June 8th

Events

Earnings calls, analyst events, roadshows and more

HUMA
Today at 08:00

Humacyte - HUMA Conference Calls
CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CASI
Today at 08:00

Casi Pharmaceuticals - CASI Conference Calls
GTEC
Today at 08:00

Greenland Technologies - GTEC Conference Calls
VERO
Today at 08:00

Venus Concept - VERO Conference Calls
EVK
Today at 08:00

Ever-Glory - EVK Conference Calls
CMMB
Today at 08:00

Chemomab Therapeutics - CMMB Conference Calls
Today at 08:30

Export Prices Y/Y: July 2022 Government Event
Today at 08:30

Import Prices M/M: July 2022 Government Event
Today at 08:30

Import Prices Y/Y: July 2022 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

NASDAQ market internals summary

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access